Journal of Pediatric Gastroenterology and Nutrition 2009-11-01

Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.

J Antonio Quiros, Melvin B Heyman, John F Pohl, Thomas M Attard, Henry J Pieniaszek, Enoch Bortey, Kelli Walker, William P Forbes

文献索引:J. Pediatr. Gastroenterol. Nutr. 49(5) , 571-9, (2009)

全文:HTML全文

摘要

: A multicenter, double-blind study was conducted to evaluate the safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate ulcerative colitis (UC).: Sixty-eight patients, 5 to 17 years of age, with mild-to-moderate active UC based on the modified Sutherland UC activity index (MUCAI) were randomized to receive oral balsalazide 2.25 or 6.75 g/day for 8 weeks. The primary endpoint was clinical improvement (reduction of the MUCAI score by > or =3 points from baseline). Clinical remission (MUCAI score of 0 or 1 for stool frequency) and histological improvement after 8 weeks were also assessed. Pharmacokinetic parameters for balsalazide, 5-aminosalicylic acid, and N-acetyl-5-aminosalicylic acid were determined at 2 weeks. Adverse events and laboratory changes were monitored throughout the study.: Clinical improvement was achieved by 45% and 37% of patients and clinical remission by 12% and 9% of patients receiving 6.75 and 2.25 g/day, respectively. Improvement in histologic grade was achieved by 8 of 16 (50%) and 3 of 10 (30%) patients receiving 6.75 and 2.25 g/day, respectively. No significant differences were seen in efficacy. Pharmacokinetics in 12 patients were characterized by large interpatient variability and low systemic exposure. Adverse events were similar between the treatment groups, the most common being headache and abdominal pain. No clinically significant changes were observed in laboratory values, including those indicative of hepatic or renal toxicity.: Balsalazide is well tolerated and improves the signs and symptoms of mild-to-moderate active UC in pediatric patients 5 to 17 years of age.


相关化合物

  • 5-乙酰氨基水杨酸

相关文献:

Simultaneous determination of 5-aminosalicylic acid, acetyl-5-aminosalicylic acid and 2,5-dihydroxybenzoic acid in endoscopic intestinal biopsy samples in humans by high-performance liquid chromatography with electrochemical detection.

1995-12-01

[J. Pharm. Biomed. Anal. 14(1-2) , 175-80, (1995)]

Radical-derived oxidation products of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid.

1994-11-04

[J. Chromatogr. B, Biomed. Appl. 661(1) , 57-68, (1994)]

Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils.

1994-01-01

[Dig. Dis. Sci. 39(1) , 145-51, (1994)]

Pharmacokinetic studies of benzalazine.

1994-12-01

[Arzneimittelforschung 44(12) , 1381-3, (1994)]

Inhibitory effect of flavonoids on the efflux of N-acetyl 5-aminosalicylic acid intracellularly formed in Caco-2 cells.

2009-01-01

[J. Biomed. Biotechnol. 2009 , 467489, (2009)]

更多文献...